Logo

Advent and GIC to Acquire Sobi for ~$8B

Share this

Advent and GIC to Acquire Sobi for ~$8B

Shots:

  • Advent and GIC to acquire Sobi for ~$8B (SEK 69.4B) at $27.33/share (SEK 235) representing a premium of 34.5% to the closing price of $20.41. The offer acceptance period is expected to start on Sept 2021 and expire on Oct 21- 2021
  • Sobi focuses on delivering innovative therapies and services in the areas of hematology- immunology- and specialty care & had a portfolio of 6 products & offices in ~ 30 countries- offering therapies for patients in ~ 70 countries
  • Agnafit Bidco will obtain ownership of 90% of the total number of Shobi’s shares & the receipt of all necessary regulatory- governmental- or similar clearances- approvals & decisions- including from competition authorities

| Ref: Sobi | Image: Sobi

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions